Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
GLOBETECH PUBLISHING
JIB

System Detects Novel Interaction Partners for Membrane Proteins

By BiotechDaily International staff writers
Posted on 14 Jun 2013
Image: The Dualmembrane Kit for identification and investigation of membrane protein interaction partners (Photo courtesy of Dualsystems Biotech AG).
Image: The Dualmembrane Kit for identification and investigation of membrane protein interaction partners (Photo courtesy of Dualsystems Biotech AG).
A system detects interactions involving integral membrane proteins or membrane-associated proteins, facilitating the identification of novel interaction partners and the investigation of interaction domains.

Dualsystems Biotech AG (Schlieren, Switzerland) introduces its “DUALmembrane System” to detect pairwise protein interactions, identify novel protein interactions by cDNA library screening, investigate ternary complexes, and map interaction domains. The system is available in both convenient kit form and as a custom screening service. The DUALmembrane System reliably detects interactions between integral membrane proteins and receptor subunits and coreceptors as well as membrane-associated proteins and soluble proteins. The system is based on properties of ubiquitin, the small protein modifier conserved in eukaryotes that plays a primary role in protein degradation.

The DUALmembrane Kit screens full-length integral membrane proteins for interactions in vivo under the physiological conditions at the membrane, with novel interactions identified through screening of cDNA libraries. The range of available cDNA libraries has recently been significantly broadened by DUALsystems for screening of human tissues, animal tissues, plant cells, and microorganisms. The kit also enables easy subcloning of full-length cDNA inserts using Sfi I technology.

With the DUALmembrane Custom Screening Service, researchers can also save time and money by leveraging Dualsystems Biotech’s extensive experience and expertise in identifying novel interaction partners for proteins of interest. Custom screening is particularly useful for detecting weak or transient interactions.

Related Links:

Dualsystems Biotech
For Membrane Proteins



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.